DNLI points to AVYLAH launch for Hunter syndrome and broader pipeline
DNLI says it is leveraging its validated platform and capital base to advance a broad pipeline, highlighted by the AVYLAH launch for Hunter syndrome and multiple enzyme replacement therapies. Clinical and biomarker readouts are expected in 2027–2028.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.